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A 
major breakthrough towards 
a greater understanding of 
the pathophysiology of severe 
mental illness came with the recent 
identiﬁ  cation of potential susceptibility 
genes for schizophrenia and bipolar 
disorder, the two main diagnostic 
categories of functional psychoses. 
Although it has been known for many 
years that schizophrenia and bipolar 
disorder tend to run in families, 
and twin and adoption studies have 
clearly established the heritability of 
both disorders, no single “gene for 
schizophrenia” or “gene for bipolar 
disorder” appears to exist. Instead, 
the pattern of inheritance suggests 
that these common mental illnesses 
are caused by many different genes of 
small effect, acting together to confer 
susceptibility. 
For schizophrenia, several 
candidate susceptibility genes have 
been identiﬁ  ed, but for all except 
one of them, the single-nucleotide 
polymorphisms found to be associated 
with the disorder are noncoding. 
Hence, changes in the expression of 
the genes (for example, in terms of 
their splicing or relative abundance), 
rather than an amino acid alteration, 
are thought to underlie their genetic 
association [1]. To investigate this 
possibility further, studies of gene 
expression in postmortem brains are 
required. 
A New Gene Expression Study
In this month’s PLoS Medicine, Linda 
Brzustowicz and colleagues present the 
results of their study of one potential 
schizophrenia susceptibility gene, 
CAPON (carboxyl-terminal PDZ ligand 
of neuronal nitric oxide synthase), 
using postmortem tissue samples of 
the dorsolateral prefrontal cortex, a 
pathological “hotspot” identiﬁ  ed in 
studies of schizophrenia [2].
The gene for CAPON is located on 
Chromosome 1q22, a locus of interest 
initially identiﬁ  ed from linkage 
studies of schizophrenia. Two studies, 
including one by Brzustowicz and 
colleagues, subsequently detected 
an association between single-
nucleotide polymorphisms within 
the CAPON gene and the occurrence 
of schizophrenia [3,4]. The role 
of CAPON in binding nitric oxide 
synthase (Figure 1) places it at the 
centre of regulation of N-methyl-D-
aspartate (NMDA) receptor–mediated 
glutamate neurotransmission, 
abnormalities of which have long 
been proposed to be involved in 
schizophrenia, lending credence to 
CAPON as a susceptibility gene for 
the disorder. However, as sequencing 
of CAPON failed to reveal a coding 
mutation, Brzustowicz and colleagues 
went on to examine whether the 
expression of the gene is altered in 
schizophrenia. 
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Figure 1. CAPON Binds Nitric Oxide Synthase, Regulating NMDA Receptor–Mediated 
Glutamate Neurotransmission
Binding of CAPON results in a reduction of NMDA receptor/nitric oxide synthase (NOS) complexes, 
leading to decreased NMDA receptor–gated calcium inﬂ  ux and a catalytically inactive nitric 
oxide synthase. Overexpression of either the full-length or the novel shortened CAPON isoform 
as reported by Brzustowicz and colleagues is, therefore, predicted to lead to impaired NMDA 
receptor–mediated glutamate neurotransmission. 
(Illustration: Bang Wong, http://www.clearscience.info)
The Perspectives section is for experts to discuss the 
clinical practice or public health implications of a 
published article that is freely available online.PLoS Medicine  |  www.plosmedicine.org 0947
First, using standard techniques, 
the authors identiﬁ  ed a novel CAPON 
mRNA transcript, and veriﬁ  ed that 
the predicted shortened protein 
was expressed in the brain. In order 
to continue on with this work, and 
determine if CAPON expression 
was altered in schizophrenia, they 
used RNA samples isolated from 
the dorsolateral prefrontal cortex of 
psychiatrically normal individuals, 
individuals with schizophrenia, and 
individuals with bipolar disorder. 
These samples were provided by the 
Stanley Medical Research Institute 
(http:⁄⁄www.stanleyresearch.org/
programs/brain_collection.asp). 
Although the authors’ primary interest 
was schizophrenia, as a condition of 
use, the Stanley Medical Research 
Institute required investigators to be 
blinded to diagnosis, and, hence, the 
experiments were run on individuals 
with bipolar disorder as well.
Using quantitative real-time 
polymerase chain reaction, the 
authors found that while the mRNA 
for the full-length CAPON protein 
was unchanged in either disorder, 
for both schizophrenia and bipolar 
disorder, mRNA expression of the 
novel shortened CAPON isoform 
was increased compared to the 
psychiatrically normal controls. 
Antipsychotic drug treatment received 
by the patients did not appear to 
underlie the authors’ ﬁ  ndings, and 
genotyping revealed that individuals 
with one or two copies of alleles 
previously identiﬁ  ed as associated with 
schizophrenia had higher levels of the 
novel CAPON isoform mRNA. The 
authors concluded that overexpression 
of either CAPON isoform would be 
expected to disrupt NMDA receptor 
function, and that the results of their 
study not only added support to the 
role of CAPON in schizophrenia, 
but also implicated the gene in the 
aetiology of bipolar disorder.
Limitations of the Study
All postmortem studies such as this are 
limited by the suitability of the material 
available, and the brain series from 
which they came. The Stanley Medical 
Research Institute series used by the 
authors is well matched for variables 
known to inﬂ  uence studies of gene 
expression, and the results of the study 
are likely to be genuine. However, 
replication in another brain series 
should be attempted. In addition, as 
this was a homogenate-based study 
of one brain region, future studies 
should examine other areas, and also 
use additional techniques (such as 
in situ hybridization histochemistry) 
to determine whether expression is 
altered in all or only speciﬁ  c neuronal 
populations. As the authors were 
limited to examining RNA, it will 
also be interesting to determine if 
expression of the encoded shortened 
CAPON protein is similarly increased 
in schizophrenia and bipolar disorder. 
Lastly, functional in vitro studies 
examining the knock-on effects of 
overexpression of the shortened 
CAPON protein may be especially 
useful for understanding the function 
of this novel isoform and the 
pathophysiological consequences of the 
authors’ ﬁ  ndings.
Conclusion
This study is an example of one 
approach that may be used to help 
us begin to understand how genes, 
such as CAPON, may confer risk for 
disease susceptibility. The paper also 
highlights the growing awareness that 
although, classically, schizophrenia 
and bipolar disorder have been 
conceptualised as separate disorders, it 
may be more appropriate to envisage 
them as phenotypical extremes of a 
continuum of disease caused by an 
overlapping set of genes [5]. Although 
the ﬁ  ndings of this study are not 
of immediate clinical relevance, a 
better understanding of the genes 
and pathways that are involved will 
ultimately lead to the development 
of more effective treatments for both 
disorders.  
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